Actionable insights straight to your inbox

Equities logo

How the Lack of R&D at Big Pharma Is Boosting Small Biotechs

The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview
When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The
Initial Jobless Claims fell 12,000 to 365,000 still above the 350,000 recessionary threshold. Non-manufacturing ISM came in at 53.7 in August, just above expectations. The Dow Jones Industrial